SELECT PUBLICATIONS

Amato RJ et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). Proc ASCO 2007;Abstract 5026.

Bajetta E et al. Renal cell cancer and sorafenib: Skin toxicity and treatment outcome. Tumori 2007;93(2):201-3. Abstract

Bukowski RM et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. Proc ASCO 2007;Abstract 5023.

Bukowski RM et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). Proc ASCO 2006;Abstract 4523.

Choueiri TK et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 2007;110(3):543-50. Abstract

Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Proc ASCO 2007;Abstract 5106.

Drabkin HA et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment. Proc ASCO 2007;Abstract 5041.

Escudier B et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-2a vs placebo/interferon-2a as first-line therapy in metastatic renal cell carcinoma. Proc ASCO 2007a;Abstract 3.

Escudier B et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007b;356(2):125-34. Abstract

Henderson CA et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Subset analysis of patients (pts) with brain metastases (BM). Proc ASCO 2007;Abstract 15506.

Knox JJ et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. Proc ASCO 2007;Abstract 5011.

Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24. Abstract

Ryan CW et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts). Proc ASCO 2007;Abstract 5096.

Sablin MP et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. Proc ASCO 2007;Abstract 5038.

Stadler WM et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). Proc ASCO 2007;Abstract 5036.

Szczylik C et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. Proc ASCO 2007;Abstract 5025.

Home

Editor
Neil Love, MD

Interviews

David I Quinn, MBBS, PhD
- Select publications

Walter Stadler, MD
- Select publications

Mario Lacouture, MD
- Select publications

Bernard J Escudier, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office